Cargando…
Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases
BACKGROUND: Hepatic steatosis commonly occurs in some chronic liver diseases and may affect disease progression. AIM: To investigate the performance of controlled attenuation parameter (CAP) for the diagnosis of hepatic steatosis in patients with autoimmune liver diseases (AILDs). METHODS: Patients...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789069/ https://www.ncbi.nlm.nih.gov/pubmed/33505152 http://dx.doi.org/10.3748/wjg.v27.i1.80 |
_version_ | 1783633159653425152 |
---|---|
author | Ni, Xi-Xi Lian, Min Wu, Hui-Min Li, Xiao-Yun Sheng, Li Bao, Han Miao, Qi Xiao, Xiao Guo, Can-Jie Li, Hai Ma, Xiong Hua, Jing |
author_facet | Ni, Xi-Xi Lian, Min Wu, Hui-Min Li, Xiao-Yun Sheng, Li Bao, Han Miao, Qi Xiao, Xiao Guo, Can-Jie Li, Hai Ma, Xiong Hua, Jing |
author_sort | Ni, Xi-Xi |
collection | PubMed |
description | BACKGROUND: Hepatic steatosis commonly occurs in some chronic liver diseases and may affect disease progression. AIM: To investigate the performance of controlled attenuation parameter (CAP) for the diagnosis of hepatic steatosis in patients with autoimmune liver diseases (AILDs). METHODS: Patients who were suspected of having AILDs and underwent liver biopsy were consistently enrolled. Liver stiffness measurement (LSM) and CAP were performed by transient elastography. The area under the receiver operating characteristic (AUROC) curve was used to evaluate the performance of CAP for diagnosing hepatic steatosis compared with biopsy. RESULTS: Among 190 patients with biopsy-proven hepatic steatosis, 69 were diagnosed with autoimmune hepatitis (AIH), 18 with primary biliary cholangitis (PBC), and 27 with AIH-PBC overlap syndrome. The AUROCs of CAP for the diagnosis of steatosis in AILDS were 0.878 (0.791-0.965) for S1, 0.764 (0.676-0.853) for S2, and 0.821 (0.716-0.926) for S3. The CAP value was significantly related to hepatic steatosis grade (P < 0.001). Among 69 patients with AIH, the median CAP score was 205.63 ± 47.36 dB/m for S0, 258.41 ± 42.83 dB/m for S1, 293.00 ± 37.18 dB/m for S2, and 313.60 ± 27.89 dB/m for S3. Compared with patients with nonalcoholic fatty liver disease (NAFLD) presenting with autoimmune markers, patients with AIH concomitant with NAFLD were much older and had higher serum IgG levels and LSM values. CONCLUSION: CAP can be used as a noninvasive diagnostic method to evaluate hepatic steatosis in patients with AILDs. Determination of LSM combined with CAP may help to identify patients with AIH concomitant with NAFLD from those with NAFLD with autoimmune phenomena. |
format | Online Article Text |
id | pubmed-7789069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-77890692021-01-26 Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases Ni, Xi-Xi Lian, Min Wu, Hui-Min Li, Xiao-Yun Sheng, Li Bao, Han Miao, Qi Xiao, Xiao Guo, Can-Jie Li, Hai Ma, Xiong Hua, Jing World J Gastroenterol Retrospective Study BACKGROUND: Hepatic steatosis commonly occurs in some chronic liver diseases and may affect disease progression. AIM: To investigate the performance of controlled attenuation parameter (CAP) for the diagnosis of hepatic steatosis in patients with autoimmune liver diseases (AILDs). METHODS: Patients who were suspected of having AILDs and underwent liver biopsy were consistently enrolled. Liver stiffness measurement (LSM) and CAP were performed by transient elastography. The area under the receiver operating characteristic (AUROC) curve was used to evaluate the performance of CAP for diagnosing hepatic steatosis compared with biopsy. RESULTS: Among 190 patients with biopsy-proven hepatic steatosis, 69 were diagnosed with autoimmune hepatitis (AIH), 18 with primary biliary cholangitis (PBC), and 27 with AIH-PBC overlap syndrome. The AUROCs of CAP for the diagnosis of steatosis in AILDS were 0.878 (0.791-0.965) for S1, 0.764 (0.676-0.853) for S2, and 0.821 (0.716-0.926) for S3. The CAP value was significantly related to hepatic steatosis grade (P < 0.001). Among 69 patients with AIH, the median CAP score was 205.63 ± 47.36 dB/m for S0, 258.41 ± 42.83 dB/m for S1, 293.00 ± 37.18 dB/m for S2, and 313.60 ± 27.89 dB/m for S3. Compared with patients with nonalcoholic fatty liver disease (NAFLD) presenting with autoimmune markers, patients with AIH concomitant with NAFLD were much older and had higher serum IgG levels and LSM values. CONCLUSION: CAP can be used as a noninvasive diagnostic method to evaluate hepatic steatosis in patients with AILDs. Determination of LSM combined with CAP may help to identify patients with AIH concomitant with NAFLD from those with NAFLD with autoimmune phenomena. Baishideng Publishing Group Inc 2021-01-07 2021-01-07 /pmc/articles/PMC7789069/ /pubmed/33505152 http://dx.doi.org/10.3748/wjg.v27.i1.80 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Retrospective Study Ni, Xi-Xi Lian, Min Wu, Hui-Min Li, Xiao-Yun Sheng, Li Bao, Han Miao, Qi Xiao, Xiao Guo, Can-Jie Li, Hai Ma, Xiong Hua, Jing Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases |
title | Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases |
title_full | Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases |
title_fullStr | Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases |
title_full_unstemmed | Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases |
title_short | Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases |
title_sort | evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases |
topic | Retrospective Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789069/ https://www.ncbi.nlm.nih.gov/pubmed/33505152 http://dx.doi.org/10.3748/wjg.v27.i1.80 |
work_keys_str_mv | AT nixixi evaluationofcontrolledattenuationparameterinassessinghepaticsteatosisinpatientswithautoimmuneliverdiseases AT lianmin evaluationofcontrolledattenuationparameterinassessinghepaticsteatosisinpatientswithautoimmuneliverdiseases AT wuhuimin evaluationofcontrolledattenuationparameterinassessinghepaticsteatosisinpatientswithautoimmuneliverdiseases AT lixiaoyun evaluationofcontrolledattenuationparameterinassessinghepaticsteatosisinpatientswithautoimmuneliverdiseases AT shengli evaluationofcontrolledattenuationparameterinassessinghepaticsteatosisinpatientswithautoimmuneliverdiseases AT baohan evaluationofcontrolledattenuationparameterinassessinghepaticsteatosisinpatientswithautoimmuneliverdiseases AT miaoqi evaluationofcontrolledattenuationparameterinassessinghepaticsteatosisinpatientswithautoimmuneliverdiseases AT xiaoxiao evaluationofcontrolledattenuationparameterinassessinghepaticsteatosisinpatientswithautoimmuneliverdiseases AT guocanjie evaluationofcontrolledattenuationparameterinassessinghepaticsteatosisinpatientswithautoimmuneliverdiseases AT lihai evaluationofcontrolledattenuationparameterinassessinghepaticsteatosisinpatientswithautoimmuneliverdiseases AT maxiong evaluationofcontrolledattenuationparameterinassessinghepaticsteatosisinpatientswithautoimmuneliverdiseases AT huajing evaluationofcontrolledattenuationparameterinassessinghepaticsteatosisinpatientswithautoimmuneliverdiseases |